- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
mHealth Remains Popular Due to Shift towards Value-Based Medicine
Mobile health (mHealth) has become progressively popular globally and offers various services to the healthcare industry-including data collection and remote patient monitoring-and is predicted to increase as the industry continues to shift toward value-based medicine, according to business intelligence provider GBI Research.
The company’s latest report states that mHealth solutions and services are a reality due to advancement in new devices, the expansion of communication network coverage, and the reduction in the retail price of wireless technologies. The market drive derives from a need for more cost-effective means to deliver healthcare, a need to demonstrate the value and effectiveness of treatments, and increasing support from healthcare professionals and reimbursement entities for mHealth solutions.
The need for more cost-effective means to deliver healthcare is regarded as the most important growth driver in the mHealth market, followed by the increasing need to demonstrate the value and effectiveness of treatments and by increasing support from healthcare professionals and reimbursement entities for mHealth solutions.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
